Calaspargase Pegol

Summary

Calaspargase Pegol (CHEMBL2108728) is an approved enzyme (ATC L01XX86); indicated across 7 conditions including acute lymphoblastic leukemia and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: L01XX86
• Indications: 7 conditions
• Clinical trials: 21

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108728
Name	Calaspargase Pegol
Type	Enzyme
Max phase	4
ATC	L01XX86

Also known as: Asparlas, Calaspargasa pegol, Calaspargase pegol, Calaspargase pegol mknl, Calaspargase pegol-mknl, EZN-2285, CALASPARGASE PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute lymphoblastic leukemia	4	MONDO:0004967	EFO:0000220
neoplasm	4	MONDO:0005070	EFO:0000616
T-cell acute lymphoblastic leukemia	3	MONDO:0004963	EFO:0000209
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
leukemia	1	MONDO:0005059	EFO:0000565
lymphoid leukemia	1	MONDO:0005402	EFO:0004289

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE2	8
PHASE3	4
PHASE1	4
PHASE2/PHASE3	3
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03007147	PHASE3	ACTIVE_NOT_RECRUITING	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03117751	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03959085	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT05602194	PHASE3	ACTIVE_NOT_RECRUITING	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT07072585	PHASE2/PHASE3	NOT_YET_RECRUITING	Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
NCT00671034	PHASE3	COMPLETED	Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT04817761	PHASE2/PHASE3	TERMINATED	SPARK-ALL: Calaspargase Pegol in Adults With ALL
NCT02981628	PHASE2	RECRUITING	Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT04546399	PHASE2	RECRUITING	A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT05192889	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
NCT05761171	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT06124157	PHASE2	RECRUITING	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06317662	PHASE2	RECRUITING	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06390319	PHASE2	RECRUITING	Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06561074	PHASE2	RECRUITING	A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
NCT06210750	PHASE2	WITHDRAWN	Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04953780	PHASE1	ACTIVE_NOT_RECRUITING	2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
NCT05034627	PHASE1	ACTIVE_NOT_RECRUITING	Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05292664	PHASE1	RECRUITING	Venetoclax Basket Trial for High Risk Hematologic Malignancies
NCT05581030	PHASE1	RECRUITING	CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT03719105	EARLY_PHASE1	RECRUITING	Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).